These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Rangwala SM; Lazar MA Trends Pharmacol Sci; 2004 Jun; 25(6):331-6. PubMed ID: 15165749 [TBL] [Abstract][Full Text] [Related]
3. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870 [TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. Henke BR J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980 [No Abstract] [Full Text] [Related]
5. Peroxisome proliferator-activated receptors as molecular targets for drug therapy. Sridhar GR J Assoc Physicians India; 2003 Jan; 51():49-52. PubMed ID: 12693455 [TBL] [Abstract][Full Text] [Related]
6. PPAR agonists in the treatment of insulin resistance and associated arterial disease. Camejo G Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Sidhu JS; Cowan D; Tooze JA; Kaski JC Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366 [TBL] [Abstract][Full Text] [Related]
8. [Peroxisome proliferator-activated receptors and atherosclerosis]. Jin N; Wang X Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):13-8. PubMed ID: 15127591 [TBL] [Abstract][Full Text] [Related]
9. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. Corti R; Osende JI; Fallon JT; Fuster V; Mizsei G; Jneid H; Wright SD; Chaplin WF; Badimon JJ J Am Coll Cardiol; 2004 Feb; 43(3):464-73. PubMed ID: 15013132 [TBL] [Abstract][Full Text] [Related]
10. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231 [TBL] [Abstract][Full Text] [Related]
12. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. Wei ZL; Kozikowski AP J Org Chem; 2003 Nov; 68(23):9116-8. PubMed ID: 14604391 [TBL] [Abstract][Full Text] [Related]
13. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand. Hirotani M; Tsukamoto T; Bourdeaux J; Sadano H; Osumi T Biochem Biophys Res Commun; 2001 Oct; 288(1):106-10. PubMed ID: 11594759 [TBL] [Abstract][Full Text] [Related]
14. Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists. Liao C; Xie A; Shi L; Zhou J; Lu X J Chem Inf Comput Sci; 2004; 44(1):230-8. PubMed ID: 14741032 [TBL] [Abstract][Full Text] [Related]
15. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C Trends Pharmacol Sci; 2003 Oct; 24(10):530-4. PubMed ID: 14559405 [No Abstract] [Full Text] [Related]
16. Antiinflammatory properties of PPARgamma agonists following ischemia. Sundararajan S; Landreth GE Drug News Perspect; 2004 May; 17(4):229-36. PubMed ID: 15334171 [TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease. Sidhu JS; Kaski JC Heart; 2001 Sep; 86(3):255-8. PubMed ID: 11514473 [No Abstract] [Full Text] [Related]
18. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. Plutzky J J Am Coll Cardiol; 2003 Nov; 42(10):1764-6. PubMed ID: 14642685 [No Abstract] [Full Text] [Related]
19. PPAR agonists in the treatment of atherosclerosis. Francis GA; Annicotte JS; Auwerx J Curr Opin Pharmacol; 2003 Apr; 3(2):186-91. PubMed ID: 12681242 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. Moller DE; Greene DA Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854 [No Abstract] [Full Text] [Related] [Next] [New Search]